Examining the effects of hormone treatment in transgender women and non-binary individuals
Feminizing Treatment in Transgender Women and Non-binary Persons BODY IDENTITY CLINIC - ESTROGEN
Odense University Hospital · NCT05169762
This study is testing how hormone treatment affects heart health over time in transgender women and non-binary individuals.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | Male |
| Sponsor | Odense University Hospital (other) |
| Locations | 1 site (Odense) |
| Trial ID | NCT05169762 on ClinicalTrials.gov |
What this trial studies
This observational cohort study involves 100 transgender women receiving gender-affirming hormone treatment. Participants will be followed for outcomes related to cardiovascular health at intervals of 1, 3, 5, and 10 years. The study aims to assess the formation of non-calcified and calcified plaques through coronary CT angiograms, evaluate heart function via echocardiograms, and measure various cardiovascular risk markers in blood and urine. The goal is to better understand the long-term cardiovascular effects of hormone therapy in this population.
Who should consider this trial
Good fit: Ideal candidates for this study are transgender women who have been assigned male at birth and are eligible for gender-affirming feminizing treatment.
Not a fit: Patients who are not transgender women or non-binary individuals, or those who do not meet the eligibility criteria for hormone treatment, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the cardiovascular risks associated with hormone treatment, leading to improved health management for transgender individuals.
How similar studies have performed: While there have been studies on hormone treatment in transgender individuals, this specific long-term observational approach focusing on cardiovascular outcomes is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * assigned male at birth and eligeble for gender affirming feminizing treatment Exclusion Criteria: none \-
Where this trial is running
Odense
- OdenseUH — Odense, Denmark (RECRUITING)
Study contacts
- Principal investigator: Dorte Glintborg — Odense University Hospital
- Study coordinator: Dorte Glintborg
- Email: dorte.glintborg@rsyd.dk
- Phone: +4565411807
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Transgenderism, gender affirming hormone treatment, estrogen, cardiovascular risk